Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of QL1203 vs Vectibix in Healthy Males
NCT04234594Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ql1203 in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Area under the plasma concentration-time curve (AUC0-t) at 36 days. Status: unknown.
02
Drugs
ql1203
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04234594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04234594.